Literature DB >> 22476945

Recent developments in the management of T-cell precursor acute lymphoblastic leukemia/lymphoma.

Adele K Fielding1, Lalita Banerjee, David I Marks.   

Abstract

T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma are uncommon disorders classified together by the World Health Organization classification as "T-lymphoblastic leukemia/lymphoma." This review gives an overview on the treatment of these aggressive but curable T cell malignancies in adult patients, in order to highlight current developments. The most interesting and relevant developments are in our understanding of the genetics of T-ALL/LBL and how the genetics relate to clinical outcome. These studies will inform clinicians as to which targeted novel agents may be of value and how patients may be best risk-stratified to receive them.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22476945     DOI: 10.1007/s11899-012-0123-4

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  82 in total

1.  Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.

Authors:  A Reiter; M Schrappe; W D Ludwig; M Tiemann; R Parwaresch; M Zimmermann; E Schirg; G Henze; G Schellong; H Gadner; H Riehm
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

Review 2.  Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

Authors:  N Gökbuget; D Hoelzer; R Arnold; A Böhme; C R Bartram; M Freund; A Ganser; M Kneba; W Langer; T Lipp; W D Ludwig; G Maschmeyer; H Rieder; E Thiel; A Weiss; D Messerer
Journal:  Hematol Oncol Clin North Am       Date:  2000-12       Impact factor: 3.722

3.  Effects of combination of notch inhibitor plus hedgehog inhibitor or Wnt inhibitor on growth of leukemia cells.

Authors:  Yuki Okuhashi; Mai Itoh; Nobuo Nara; Shuji Tohda
Journal:  Anticancer Res       Date:  2011-03       Impact factor: 2.480

Review 4.  Journey through the thymus: stromal guides for T-cell development and selection.

Authors:  Yousuke Takahama
Journal:  Nat Rev Immunol       Date:  2006-02       Impact factor: 53.106

Review 5.  Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

Authors:  M Brüggemann; A Schrauder; T Raff; H Pfeifer; M Dworzak; O G Ottmann; V Asnafi; A Baruchel; R Bassan; Y Benoit; A Biondi; H Cavé; H Dombret; A K Fielding; R Foà; N Gökbuget; A H Goldstone; N Goulden; G Henze; D Hoelzer; G E Janka-Schaub; E A Macintyre; R Pieters; A Rambaldi; J-M Ribera; K Schmiegelow; O Spinelli; J Stary; A von Stackelberg; M Kneba; M Schrappe; J J M van Dongen
Journal:  Leukemia       Date:  2009-12-24       Impact factor: 11.528

6.  High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group.

Authors:  J W Sweetenham; G Santini; W Qian; M Guelfi; N Schmitz; S Simnett; A Nagler; H Holte; S Kvaloy; P Bruzzi; A H Goldstone
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

7.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.

Authors:  Elaine Coustan-Smith; Charles G Mullighan; Mihaela Onciu; Frederick G Behm; Susana C Raimondi; Deqing Pei; Cheng Cheng; Xiaoping Su; Jeffrey E Rubnitz; Giuseppe Basso; Andrea Biondi; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Lancet Oncol       Date:  2009-01-13       Impact factor: 41.316

8.  CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia.

Authors:  Silvia Buonamici; Thomas Trimarchi; Maria Grazia Ruocco; Linsey Reavie; Severine Cathelin; Brenton G Mar; Apostolos Klinakis; Yevgeniy Lukyanov; Jen-Chieh Tseng; Filiz Sen; Eric Gehrie; Mengling Li; Elizabeth Newcomb; Jiri Zavadil; Daniel Meruelo; Martin Lipp; Sherif Ibrahim; Argiris Efstratiadis; David Zagzag; Jonathan S Bromberg; Michael L Dustin; Iannis Aifantis
Journal:  Nature       Date:  2009-06-18       Impact factor: 49.962

9.  Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.

Authors:  Hagop Kantarjian; Varsha Gandhi; Jorge Cortes; Srdan Verstovsek; Min Du; Guillermo Garcia-Manero; Francis Giles; Stefan Faderl; Susan O'Brien; Sima Jeha; Jan Davis; Zeev Shaked; Adam Craig; Michael Keating; William Plunkett; Emil J Freireich
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

10.  Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.

Authors:  Pedro J Real; Valeria Tosello; Teresa Palomero; Mireia Castillo; Eva Hernando; Elisa de Stanchina; Maria Luisa Sulis; Kelly Barnes; Catherine Sawai; Irene Homminga; Jules Meijerink; Iannis Aifantis; Giuseppe Basso; Carlos Cordon-Cardo; Walden Ai; Adolfo Ferrando
Journal:  Nat Med       Date:  2008-12-21       Impact factor: 53.440

View more
  5 in total

1.  Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.

Authors:  Betty Ky Hamilton; Lisa Rybicki; Donna Abounader; Kehinde Adekola; Anjali Advani; Ibrahim Aldoss; Veronika Bachanova; Asad Bashey; Stacey Brown; Marcos DeLima; Steven Devine; Christopher R Flowers; Siddharth Ganguly; Madan Jagasia; Vanessa E Kennedy; Dennis Dong Hwan Kim; Joseph McGuirk; Vinod Pullarkat; Rizwan Romee; Karamjeet Sandhu; Melody Smith; Masumi Ueda; Auro Viswabandya; Khoan Vu; Sarah Wall; Simon B Zeichner; Miguel-Angel Perales; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2017-04-07       Impact factor: 5.742

2.  CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis.

Authors:  Wenli Zheng; L Jeffrey Medeiros; Ken H Young; Maitrayee Goswami; Linda Powers; Hagop H Kantarjian; Deborah A Thomas; Jorge E Cortes; Sa A Wang
Journal:  Leuk Lymphoma       Date:  2013-08-13

3.  Canine T-zone lymphoma: unique immunophenotypic features, outcome, and population characteristics.

Authors:  D M Seelig; P Avery; T Webb; J Yoshimoto; J Bromberek; E J Ehrhart; A C Avery
Journal:  J Vet Intern Med       Date:  2014-03-21       Impact factor: 3.333

4.  Polyphenols are responsible for the proapoptotic properties of pomegranate juice on leukemia cell lines.

Authors:  Haytham Dahlawi; Nicola Jordan-Mahy; Malcolm Clench; Gordon J McDougall; Christine Lyn Maitre
Journal:  Food Sci Nutr       Date:  2013-02-20       Impact factor: 2.863

5.  Combination Effect of Notch1 and PI3K/AKT/mTOR Signaling Pathways Inhibitors on T-ALL Cell Lines.

Authors:  Halimeh Khoshamooz; Saeid Kaviani; Amir Atashi; Seyed Hossein Mirpour Hassankiadeh
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2020-04-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.